Table 2.
Description and comparison of clinical variables of the two study groups.
| Group | p-Value | ||
|---|---|---|---|
| Controls | Patients | ||
| No. drugs | 4.81 (3.45) | 5.39 (2.18) | 0.225 |
| BMI | 26.95 (3.77) | 28 (4.4) | 0.281 |
| Cardiovascular disease | 48 (57.8) | 39 (56.5) | 0.871 |
| Endocrine disease | 48 (57.8) | 35 (50.7) | 0.381 |
| Respiratory disease | 17 (20.5) | 26 (37.7) | 0.019 |
| Locomotor disease | 47 (56.6) | 48 (69.6) | 0.101 |
| Gastrointestinal disease | 30 (36.1) | 15 (21.7) | 0.049 |
| Hematological disease | 29 (34.9) | 30 (43.5) | 0.282 |
| Urogenital disease | 30 (36.1) | 42 (60.9) | 0.002 |
BMI: Body mass index. Statistical significance was established as p < 0.05.